Robert B. Bazemore - 17 Sep 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact for Robert B. Bazemore
Issuer symbol
AKTX
Transactions as of
17 Sep 2024
Net transactions value
$0
Form type
4
Filing time
18 Sep 2024, 16:40:20 UTC
Previous filing
05 Sep 2024
Next filing
10 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +5,000,000 $0.000000 5,000,000 17 Sep 2024 Ordinary Shares, par value $0.0001 per share 5,000,000 $0.001700 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share ("Ordinary Share").
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Remarks:

Exhibit 24 - Power of Attorney